We first derived the gene expression signature of the SETD2_Y1666C mutation based on its RNA-seq results, as described in a previous study.11 Referring to 91 RNA-seq samples from 54 patients in a melanoma cohort treated with anti-PD-1,56 we confirmed that the SETD2_Y1666C-mutation signature was positively correlated with tumor PD-L1, MHC-I, and cytotoxic T-cell infiltration (Fig. 6g). The gene discussed is CD274; the disease is neoplasm.